Kornimate/medical-research-clean huggingface dataset:
single-session web-based training in self-compassion

Conditions: Stress; Anxiety; Depression

Summary: two-arm, parallel group randomized clinical trial conducted via mturk comparing a single-session web-based intervention called compassionate care versus a control intervention (nature videos with relaxing music) for adults with moderate-to-severe stress, depression and/or anxiety symptoms.

procedures include completing: (1) pre-intervention baseline assessment; (2) one of two single-session web-based intervention (approximately 30 to 45 minutes each); (3) a brief post-intervention survey; and (4) a 2-week follow-up assessment.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * fluent in english * at least moderate stress, anxiety and/or depressive symptoms, as indicated by a score of: 14 or higher on the pss-10, and/or 10 or higher on the gad-7, and/or 10 or higher on the phq-9 exclusion criteria: * fail to meet above-listed inclusion criteria * do not pass attention/data quality checks in initial screening or study assessments, including: * obvious lack of english fluency in open response questions * responding with random text in open response questions * respond with either copy/pasted responses from text earlier in the intervention to any of free response questions * participants with a completion time less than an average of 1.5 seconds per question for the baseline survey assessment or who fail all three attention check questions in the baseline survey, indicating very careless, random, inattentive and/or hasty responding * exit the study prior to condition randomization

Keywords: randomized controlled trial self-compassion
capecitabine, carboplatin and weekly paclitaxel for patients with solid tumors and adenocarcinoma of unknown primary

Conditions: Tumors; Unknown Primary Tumors; Adenocarcinoma

Summary: this study will determine the maximum tolerated dose of the triplet combination of capecitabine that can be administered in combination with weekly paclitaxel and every four weeks with carboplatin.

rationale: the combination of the chemotherapy drugs paclitaxel and carboplatin is one of the most common combination regimens used in clinical practice for cancer. these agents are used for a variety of cancers. the current study builds on previous research about treatment schedules for administering these agents to reduce toxicity and optimize efficacy. the phase i and ii portions of the current study combine paclitaxel and carboplatin with capecitabine in patients. researchers are seeking to identify the highest dose of capecitabine and paclitaxel in combination with carboplatin for this patient population, as well as to gather information about preliminary efficacy. purpose: the phase i portion of this study will evaluate the maximum tolerated dose of capecitabine and paclitaxel in combination with carboplatin for patients. the phase ii portion of this study will assess the objective response rate in patients using the same treatment combination. toxicities will be closely measured in both phases of the study. treatment: patients in this study will be given capecitabine, carboplatin, and paclitaxel. capecitabine will be given through oral pills. carboplatin and paclitaxel will be given through intravenous infusions. treatment drugs will be given on a four-week cycle. carboplatin will be administered on day 1, paclitaxel weekly for the first 3 weeks, and capecitabine twice daily on days 8 through 21 of each cycle. no treatments will be given during the fourth week of each treatment cycle. during the phase i portion of the study, patients may receive different doses of capecitabine and paclitaxel since the purpose is to identify the maximum tolerated dose of each drug in combination with carboplatin. once the maximum tolerated dose of these agents is identified during phase i, the phase ii portion of the study will begin. treatments will be discontinued due to disease growth or unacceptable side effects. several tests and exams will be given throughout the study to closely monitor patients.

Eligibility criteria:
inclusion criteria for phase i: * all advanced solid malignancies * any prior chemotherapy permitted * performance status 0-2 inclusion criteria for phase ii: * adenocarcinoma of unknown primary * no prior chemo permitted * performance status 0-2

Keywords: adenocarcinoma
predictors and outcomes of dysglycemia in pheochromocytoma and paraganglioma

Conditions: Pheochromocytoma; Paraganglioma

Summary: the investigators will retrospectively analyze the clinical data of consecutive patients with pheochromocytomas and paragangliomas admitted between january 2018 and june 2020. the clinical characteristics of patients with and without dysglycemia will be compared, and whether surgery could improve the patients'dysglycemia will be also investigated.

this retrospective cohort study will include all consecutive adult patients who underwent surgery for pheos and catecholamine-secreting pgls from january 2018 to june 2020. patients with recurrent ppgls, those who required steroids after adrenalectomy, and those with inadequate clinical records were excluded. the patients' electronic medical files were reviewed. patients with dysglycemia included those with diabetes, or impaired fasting glucose, or impaired glucose tolerance. clinical history data such as age, sex, body mass index (bmi), the presence of preoperative symptoms, biochemical test results, and tumor characteristics, such as tumor diameters and locations were extracted and analyzed.

Eligibility criteria:
inclusion criteria: * age ≥18 years old * patients with surgical pathological diagnosis of pheochromocytomas and paragangliomas(ppgls) exclusion criteria: * recurrent ppgls * patients who required steroids after adrenalectomy * patients with inadequate clinical records were excluded.

Keywords: pheochromocytoma paraganglioma dysglycemia
turkish reliability and validity of fopqc-sf

Conditions: Fear; Pain; Juvenile Idiopathic Arthritis

Summary: the aim of this study is to question the turkish validity and reliability of the "the fear of pain questionnaire for children short form (fopqc-sf)" scale. children/adolescents between the ages of 7-18 and diagnosed with juvenile idiopathic arthritis followed by the pediatric rheumatology clinic will be included in the study. the sample size of this study was determined as at least 50. to assess the validity of the fopqc-sf scale, participants will be administered the pediatric quality of life inventory (pedsql) 3.0 arthritis module, the childhood health assessment questionnaire (chaq), and the juvenile arthritis disease activity score.


Eligibility criteria:
inclusion criteria: * being diagnosed with jia according to the ilar classification * 7-18 years old * agree to participate in the study exclusion criteria: * psychiatric illness that may affect cooperation, * those with heart failure and lung pathology at a level that will affect their daily life activities
patient specific implant versus miniplates for advancement of hypoplastic maxilla

Conditions: Cleft Lip and Palate

Summary: distraction osteogenesis is the treatment of choice in management of severe maxillary anteroposterior deficiency allowing for a progressive bone generation and simultaneous expansion of the surrounding scarred soft tissue \& better long-term stability \& less relapse rate.

maxillary distraction using rigid external distraction device (red) with skeletal anchorage in cleft lip and palate overcomes the disadvantages of tooth brone red \& showed reliable advancement \& reasonable relapse rate in the short \& long-term follow up \& most importantly it solved somehow counterclockwise rotation of maxilla but still it can occur. positioning of plates in relation to center of resistance of maxilla to adjust vector of distraction can be done now by using virtual surgical planning (vsp) \& fabrication of patient specific implants (psi) to overcome problems encountered with use of conventional miniplates during distraction process. limited data in literature with no randomized clinical trials were done to assess distraction effectiveness using psi in red with skeletal anchorage and its effect on velopharyngeal insufficiency (vpi) \& speech. based on that data, the research will compare distraction effectiveness, vpi \& speech between using either psi implants or miniplates for distraction.

Eligibility criteria:
inclusion criteria: 1. non growing cleft patients, age range (18-30 years) 2. unilateral or bilateral cleft patients 3. anteroposterior deficiency (1.5-2.5 cm) 4. no sex predilection exclusion criteria: 1. syndromic patients. 2. bone metabolism \& systemic diseases.
nifedipine versus indomethacin in the treatment of preterm labour

Conditions: Obstetric Labor, Premature

Summary: the purpose of this study was to compare the effectiveness of nifedipine versus indomethacin as tocolytic for the treatment of preterm labour with short cervix (\< 2.5cms).


Eligibility criteria:
inclusion criteria: * pregnant women between 24 and 34 weeks of gestation. * cervical length (determined by transvaginal ultrasound) of 2.5 cms or less exclusion criteria: * all contraindications for tocolysis (fetal distress, abruptio placenta). * multiple pregnancy. * all contraindications for the use of any of the two drugs (indomethacin or nifedipine).

Keywords: obstetric labor, premature short cervix nifedipine indomethacin
implementability and effectiveness of the safety planning intervention for suicidal behavior

Conditions: Suicide; Suicide, Attempted; Suicidal Ideation

Summary: the safety plan intervention (spi) has demonstrated to reduce suicide reattempts and to increase the ambulatory follow-up in american war veterans. this study evaluates the implementability and effectiveness in a significantly different population in a real world setting.

we will perform a effectiveness-implementation hybrid design (curran et al. 2012) to study firstly the feasibility of implementing the spi in our clinical setting and secondly its effectiveness. the experimental arm will consist in a group of patients who visit the ed for a suicide-related concern in which the spi is performed. this will be in the emergency department , unless for clinical reasons, the ed psychiatrist decide to postpone it to the first psychiatric appointment (which will be before one week of the ed visit as part of the treatment as usual). right after the spi is performed, both the patient and the clinician will complete questionnaire with satisfaction and acceptability measures. subjects will be followed for 6 months. at this time medical records will be consulted to obtain suicide reattempts rates and follow-up adherence. at all times, the anonymity of the participants will be preserved and will require heading of informed consent, as well as other ethical aspects indicated by the ethics committee.

Eligibility criteria:
inclusion criteria: 1. suicide attempt or presence of severe suicidal ideation 2. signed informed consent form exclusion criteria: 1. less than 18 years old 2. hospitalization in the psychiatry department 3. inability to understand the safety planning intervention withdrawal criteria: 1) participant's decision to withdraw from the trial

Keywords: suicide suicidal behavior suicidal attempt suicide prevention safety planning intervention
a phase 1 absolute bioavailability study for oral crizotinib in healthy volunteers

Conditions: Healthy

Summary: this study will be an open-label, randomized, 2-period, 2-treatment, 2-sequence, cross-over single-dose study to test the absolute bioavailability of oral crizotinib formulation to iv formulation in healthy adult volunteers. fourteen (14) subjects will be enrolled to obtain at least 12 evaluable subjects who complete the study. each subject will receive two treatments (a and b) with a washout period of at least 14 days between each treatment.

evaluate the absolute bioavailability of oral crizotinib to iv crizotinib.

Eligibility criteria:
inclusion criteria: * healthy male and/or female of non-childbearing potential subjects between the ages of 18 and 55 years, inclusive (healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ecg and clinical laboratory tests). * body mass index (bmi) of 17.5 to 30.5 kg/m\^2; and a total body weight \>50 kg (110 lbs) exclusion criteria: * evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). * any condition possibly affecting drug absorption (eg, gastrectomy). * a positive urine drug screen. * history of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males within 6 months of screening. * treatment with an investigational drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first dose of study medication. * 12-lead ecg demonstrating qtc \>450 msec at screening. * pregnant or nursing females; females of childbearing potential, including those with tubal ligation. * use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. herbal supplements and hormone replacement therapy must be discontinued 28 days prior to the first dose of study medication. * other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study. * a positive serology for hepatitis b or hepatitis c. * subjects who are currently smoking.

Keywords: healthy volunteers crizotinib absolute bioavailability pharmacokinetics
treating obese pcos patients with lsg vs. met

Conditions: Polycystic Ovary Syndrome

Summary: polycystic ovary syndrome (pcos) is a common endocrine disorder, with a prevalence of 5% to 15% in premenopausal women. patients with pcos presents as abnormal menstruation, ovulation disorders and/or hyperandrogenemia, and often accompanied by insulin resistance and other metabolic abnormalities. sleeve gastrectomy was an effective threapy for severe obesity patients. this study will evaluate the clinical efficacy of sleeve gastrectomy for obese patients with pcos. mealwhile, the specific mechanism of sleeve gastrectomy for improving obese patients with pcos will be explored through multi-group analysis.


Eligibility criteria:
inclusion criteria: * female aged 18- 45; * meet rotterdam criteria; * bmi ≥ 28 kg /m2. exclusion criteria: * women who are pregnant or have a pregnancy plan within six months; * women who are reluctant to undergo metabolic surgery; * congenital adrenocortical hyperplasia; * hyperprolactinemia; * hyperthyroidism or hypothyroidism; * abnormal liver function (≥ 3 times of the upper limit of normal range); abnormal · rrenal function (gfr\<60ml/min/1.73m2); * adrenal or ovarian tumors secreting androgens; * used contraceptives, metformin, glp-1ra, pioglitazone and contraceptives in the last 3 month.
the efficacy of chlorella supplementation on health and performance following a 12-week training programme

Conditions: Sedentary; Overweight

Summary: algae are an emerging functional food source that are gaining traction and popularity in biopharmaceutical, nutraceutical, and biotechnology industries. they are a diverse and complex species that comprise an abundant breadth of micronutrients (multiple vitamins, minerals, fatty acids, and amino acids) that can possibly promote human health. one such popular algae is chlorella, a unicellular dark green organism, which can be readily bought in health stores worldwide. although there is some promising data to suggest chlorella supplementation can alleviate cardiovascular risk factors and improve vo2max from supplementation alone, an area which has particularly limited existing literature is the possible ergogenic and health influence of chlorella supplementation combined with a controlled training programme in sedentary and overweight populations. given that such populations are susceptible to increased risk of developing associated diseases (cardiovascular disease, diabetes, hypertension) and possess poor diets, there is a need to investigate the possible synergistic effect of a training programme and supplementation of algae further. furthermore, there is growing evidence to suggest that supplementation with algae may have a beneficial effect on cognitive function, primarily owed to antioxidant and anti-inflammatory mechanisms. therefore, the purpose of this study aims to assess the efficacy of chlorella supplementation on vo2max, blood lipid profiles, cognitive function and body composition following a 12-week training programme. briefly, in a double blind, randomised, placebo-controlled trial, participants will be randomly allocated into 1 of 4 groups (a. exercise + chlorella, b. exercise + placebo, c. control + chlorella, d. control + placebo).


Eligibility criteria:
inclusion criteria: * aged 18-50 * classified a sedentary (\<30 minutes of moderate intensity exercise for \<3 days per week for 3 months) and/or overweight (bmi = 25 +) * be willing to complete a 12-week training programme exclusion criteria: * individuals taking blood thinners. * known allergies to algae/mould and iodine. * taking immunosuppressant medication * regularly ingesting algae * smokers
convection enhanced delivery of csf in dbs for parkinson's

Conditions: Parkinson Disease

Summary: this study will evaluate safety foremost but also the distribution and initial effectiveness of infusion-enhanced, mri-guided dbs for patients with medication-refractory, parkinson's disease

this is an open-label, single-arm, pilot study investigating the safety and feasibility of infusion-enhanced, mri-guided dbs electrode placement. the investigators intend to enroll patients with parkinson's disease and medically-refractory motor symptoms, who are already planned for mri-guided dbs electrodes under general anesthesia. the hypothesis of the study is that a convective micro-infusion of autologous csf will enhance the t2-weighted mri visualization of the targeted nucleus during image-guided dbs surgery for parkinson's disease. the investigators will record standard clinical measures of pd at baseline and 6 months following dbs surgery. the study will recruit patients at a rate of approximately one a month and will take less than two years to complete.

Eligibility criteria:
inclusion criteria: 1. men and women, age 30 years and older 2. subjects with advanced pd who are scheduled for mri-guided dbs surgery under general anesthesia 3. subjects who are able and willing to give informed consent and able to attend clinic visits through 6 months 4. the target nucleus, gpi or stn, is visible on mri so that it can be targeted for the study infusion and then for mri-guided dbs exclusion criteria: 1. dbs surgery planned in the awake condition with microelectrode recordings and clinical testing 2. spinal pathology not amenable to lumbar puncture 3. subjects who have had deep brain stimulation or a prior stereotactic ablation of the basal ganglia 4. legal incapacity or limited legal capacity as determined by the neuropsychologist 5. are participating or have participated in another clinical trial in the last 30 days 6. any illness that in the investigator's opinion preclude participation in this study.

Keywords: dbs
comparative study of aesculap optilene® mesh elastic versus ethicon ultrapro® mesh in incisional hernia repair

Conditions: Incisional Hernia Repair

Summary: optilene® mesh elastic and ultrapro® mesh will be used for incisional hernia repair. the primary objective of this clinical study is to demonstrate that optilene® mesh elastic is superior to ultrapro® mesh in incisional hernia repair in matter of the physical function score from the sf-36 questionnaire 21 days after mesh insertion. secondary objectives include the patient's daily activity, the rating of patients pain and the wound assessment determined on several occasions during the six months observation time.


Eligibility criteria:
inclusion criteria: * female or male patients \>=18 years * female patients are incapable of pragnancy or must be using adequate contraception and are not in lactation * patients wiht vertical aponeurotic incisions only * incisional hernia with hernia size \>= 3 cm * patient is capable to understand and to follow the instructions * written informed consent * no mesh implantation at the same site during a previous operation * immune competence of patient exclusion criteria: * simultanous participation in an investigational drug or medical device study * patients \< 18 years old * incisional hernia withe a hernia size \< 3 cm * repair of an acute incarcerated hernia * previous mesh repair at the same site * patient with other than vertical aponeurotic incisions * enterotomy to be performed during hernia repair at surgery * patient is on anti-coagulations-therapy * patient is known or assessed to be non-compliant * additional surgical treatment at the same time (e.g. cholecystectomy) * immune incompetence of patient (e.g. chemotherapy)

Keywords: large pore size propylene mesh incisional hernia randomized controlled double-blind study
waist circumference measurements in schizophrenic patients

Conditions: Waist Circumference Measurements; Schizophrenia; Cardiovascular Risk Factor

Summary: the prevalence of metabolic syndrome(ms) among pt's with schizophrenia has been reported to be high, ranging from 24 to 43% in males and 27 to 52% in females. schizophrenic patients with ms have an increased incidence of dm, coronary heart disease and increased mortality from cardiovascular diseases. central adiposity is highly correlated with the presence of hypertension, coronary heart disease, type 2 diabetes, and increased mortality risk. waist circumference(wc) is a better indicator of abdominal obesity and a better predictor of cvd than either bmi or waist-to-hip ratio. however, currently there is no standard location for the measurement of wc. objectives: 1. to compare the magnitude of wc measured at 3 sites ( immediately above the iliac crest, midpoint between the lowest rib and the iliac crest , umbilical level) in males and females. 2. to examine the correlation of wc with triglyceride, cholesterol, hdl, ldl and glucose.


Eligibility criteria:
inclusion criteria: * • patients with schizophrenia or schizoaffective disorder (dsm-iv 295) age 18 till 65 years old. * body weight change less than 1 kg in previous one month before index date. exclusion criteria: * • patients with a previous hyperlipidemia diagnosis or antilipemic prescription during the preceding 30 days. * patients received any anti-hypertensives or oral hypoglycemic agents. * pregnant or breast-feeding women.